In This Article:
As markets have welcomed easing inflation and better-than-expected economic data, the Canadian TSX has rebounded by over 5%, signaling a return of positive sentiment. With central banks potentially cutting rates and broader market leadership emerging, now is an opportune time to explore promising small-cap stocks that could benefit from these favorable conditions.
Top 10 Undiscovered Gems With Strong Fundamentals In Canada
Name | Debt To Equity | Revenue Growth | Earnings Growth | Health Rating |
---|---|---|---|---|
TWC Enterprises | 6.74% | 10.99% | 25.68% | ★★★★★★ |
Jaguar Mining | 1.19% | 5.49% | 5.12% | ★★★★★★ |
Taiga Building Products | NA | 6.05% | 10.50% | ★★★★★★ |
Amerigo Resources | 12.87% | 7.49% | 12.97% | ★★★★★☆ |
Reconnaissance Energy Africa | NA | 31.73% | -6.92% | ★★★★★☆ |
Firan Technology Group | 17.91% | 3.75% | 23.32% | ★★★★★☆ |
Mako Mining | 22.90% | 38.12% | 54.79% | ★★★★★☆ |
Pizza Pizza Royalty | 15.66% | 3.64% | 3.95% | ★★★★☆☆ |
Queen's Road Capital Investment | 7.20% | 22.14% | 22.20% | ★★★★☆☆ |
Genesis Land Development | 53.32% | 25.58% | 47.05% | ★★★★☆☆ |
Let's review some notable picks from our screened stocks.
Cipher Pharmaceuticals
Simply Wall St Value Rating: ★★★★★★
Overview: Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada with a market cap of CA$407.88 million.
Operations: Cipher Pharmaceuticals generates revenue primarily through its Specialty Pharmaceuticals segment, amounting to CA$22.16 million.
Cipher Pharmaceuticals, a small cap player in the Canadian market, is trading at 59.9% below its estimated fair value and boasts high-quality earnings. Despite having no debt now compared to five years ago when its debt-to-equity ratio was 50.1%, the company experienced negative earnings growth of -19.4% over the past year. Recent Q2 results showed stable revenue at US$5.3 million and net income of US$3 million, with basic EPS from continuing operations steady at US$0.12.
-
Take a closer look at Cipher Pharmaceuticals' potential here in our health report.
-
Explore historical data to track Cipher Pharmaceuticals' performance over time in our Past section.
Leon's Furniture
Simply Wall St Value Rating: ★★★★★★
Overview: Leon's Furniture Limited, with a market cap of CA$1.98 billion, operates as a retailer of home furnishings, mattresses, appliances, and electronics in Canada.
Operations: Leon's Furniture Limited generates revenue primarily through the sale of home furnishings, mattresses, appliances, and electronics amounting to CA$2.53 billion. The company's net profit margin stands at 7.5%.
Leon's Furniture has shown solid performance with its debt to equity ratio dropping from 20.4% to 10.4% over the past five years, indicating a stronger balance sheet. The company reported CAD 617.66 million in sales for Q2 2024, up from CAD 593.84 million a year ago, and net income rose to CAD 30.17 million from CAD 27.42 million in the same period last year. Additionally, Leon's increased its quarterly dividend by $0.02 to $0.20 per share, reflecting confidence in future earnings growth of around 2.75% annually.